My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 218

    1.

    Streptokinase and recombinant tissue plasminogen activator (rt-PA) are equally effective in treating acute myocardial infarction.

    Sherry S, Marder VJ.

    Ann Intern Med. 1991 Mar 1;114(5):417-23. Review.PMID: 1899546 [PubMed - indexed for MEDLINE]Related articles

    2.

    New developments in thrombolytic therapy.

    Collen D, Gold HK.

    Adv Exp Med Biol. 1990;281:333-54. Review.PMID: 2129372 [PubMed - indexed for MEDLINE]Related articles

    3.

    Is survival in acute myocardial infarction related to thrombolytic efficacy or the open-artery hypothesis? A controversy to be investigated with GUSTO.

    Bates ER.

    Chest. 1992 Apr;101(4 Suppl):140S-150S. Review.PMID: 1555479 [PubMed - indexed for MEDLINE]Related articlesFree article

    4.

    Efficacy of streptokinase, but not tissue-type plasminogen activator, in achieving 90-minute patency after thrombolysis for acute myocardial infarction decreases with time to treatment. PERM Study Group. Prospective Evaluation of Reperfusion Markers.

    Steg PG, Laperche T, Golmard JL, Juliard JM, Benamer H, Himbert D, Aubry P.

    J Am Coll Cardiol. 1998 Mar 15;31(4):776-9.PMID: 9525545 [PubMed - indexed for MEDLINE]Related articles

    5.

    New developments in thrombolytic therapy.

    Collen DC, Gold HK.

    Thromb Res Suppl. 1990;10:105-31. Review.PMID: 2180114 [PubMed - indexed for MEDLINE]Related articles

    6.

    A prospective, randomized trial comparing combination half-dose tissue-type plasminogen activator and streptokinase with full-dose tissue-type plasminogen activator. Kentucky Acute Myocardial Infarction Trial (KAMIT) Group.

    Grines CL, Nissen SE, Booth DC, Gurley JC, Chelliah N, Wolf R, Blankenship J, Branco MC, Bennett K, DeMaria AN.

    Circulation. 1991 Aug;84(2):540-9.PMID: 1907228 [PubMed - indexed for MEDLINE]Related articles

    7.

    Designing thrombolytic agents: focus on safety and efficacy.

    Collen D.

    Am J Cardiol. 1992 Jan 3;69(2):71A-81A. Review.PMID: 1729881 [PubMed - indexed for MEDLINE]Related articles

    8.

    The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. The GUSTO Angiographic Investigators.

    [No authors listed]

    N Engl J Med. 1993 Nov 25;329(22):1615-22. Erratum in: N Engl J Med 1994 Feb 17;330(7):516. PMID: 8232430 [PubMed - indexed for MEDLINE]Related articlesFree article

    9.

    Influence of time to treatment on early infarct-related artery patency after different thrombolytic regimens. ALKK-Study Group.

    Zeymer U, Tebbe U, Essen R, Haarmann W, Neuhaus KL.

    Am Heart J. 1999 Jan;137(1):34-8.PMID: 9878934 [PubMed - indexed for MEDLINE]Related articles

    10.

    Evaluation of a prolonged infusion of recombinant tissue-type plasminogen activator (Duteplase) in preventing reocclusion following successful thrombolysis in acute myocardial infarction.

    Kalbfleisch J, Thadani U, LittleJohn JK, Brown G, Magorien R, Kutcher M, Taylor G, Maddox WT, Campbell WB, Perry J Jr, et al.

    Am J Cardiol. 1992 May 1;69(14):1120-7.PMID: 1575179 [PubMed - indexed for MEDLINE]Related articles

    11.

    Alteplase: a pharmacoeconomic evaluation of its use in the management of myocardial infarction.

    Barradell LB, Goa KL.

    Pharmacoeconomics. 1995 Nov;8(5):428-59. Review.PMID: 10172669 [PubMed - indexed for MEDLINE]Related articles

    12.

    Comparison of front-loaded recombinant tissue-type plasminogen activator, anistreplase and combination thrombolytic therapy for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 4 trial.

    Cannon CP, McCabe CH, Diver DJ, Herson S, Greene RM, Shah PK, Sequeira RF, Leya F, Kirshenbaum JM, Magorien RD, et al.

    J Am Coll Cardiol. 1994 Dec;24(7):1602-10.PMID: 7963104 [PubMed - indexed for MEDLINE]Related articles

    13.

    A new thrombolytic regimen for acute myocardial infarction using combination half dose tissue-type plasminogen activator with full dose streptokinase: a pilot study. KAMIT Study Group.

    Grines CL, Nissen SE, Booth DC, Branco MC, Gurley JC, Bennett KA, DeMaria AN.

    J Am Coll Cardiol. 1989 Sep;14(3):573-80.PMID: 2504797 [PubMed - indexed for MEDLINE]Related articles

    14.

    Effect of intravenous streptokinase as compared with that of tissue plasminogen activator on left ventricular function after first myocardial infarction.

    White HD, Rivers JT, Maslowski AH, Ormiston JA, Takayama M, Hart HH, Sharpe DN, Whitlock RM, Norris RM.

    N Engl J Med. 1989 Mar 30;320(13):817-21.PMID: 2494454 [PubMed - indexed for MEDLINE]Related articles

    15.

    Coronary thrombolysis: streptokinase or recombinant tissue-type plasminogen activator?

    Collen D.

    Ann Intern Med. 1990 Apr 1;112(7):529-38. Review.PMID: 2107781 [PubMed - indexed for MEDLINE]Related articles

    16.

    Six- and twelve-month follow-up of the phase I Thrombolysis in Myocardial Infarction (TIMI) trial.

    Dalen JE, Gore JM, Braunwald E, Borer J, Goldberg RJ, Passamani ER, Forman S, Knatterud G.

    Am J Cardiol. 1988 Aug 1;62(4):179-85. Erratum in: Am J Cardiol 1988 Nov 15;62(16):1151. PMID: 3135737 [PubMed - indexed for MEDLINE]Related articles

    17.

    [Comparative randomized study of the effectiveness of intravenous recombinant tissue-type plasminogen activator and intravenous streptokinase in patients with acute myocardial infarct. Report of the European Cooperative Study Group for Recombinant Tissue-Type Plasminogen Activator]

    Verstraete M, Bory M, Collen D, Erbel R, Lennane RJ, Mathey D, Michels HR, Schartl M, Uebis R, Bernard R, et al.

    Klin Wochenschr. 1988;66 Suppl 12:77-85. German. PMID: 3126348 [PubMed - indexed for MEDLINE]Related articles

    18.

    Plasminogen Activator Italian Multicenter Study (PAIMS): comparison of intravenous recombinant single-chain human tissue-type plasminogen activator (rt-PA) with intravenous streptokinase in acute myocardial infarction.

    Magnani B.

    J Am Coll Cardiol. 1989 Jan;13(1):19-26.PMID: 2491867 [PubMed - indexed for MEDLINE]Related articles

    19.

    Combined tissue-type plasminogen activator and prostacyclin therapy for acute myocardial infarction. Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 4 Study Group.

    Topol EJ, Ellis SG, Califf RM, George BS, Stump DC, Bates ER, Nabel EG, Walton JA, Candela RJ, Lee KL, et al.

    J Am Coll Cardiol. 1989 Oct;14(4):877-84.PMID: 2477426 [PubMed - indexed for MEDLINE]Related articles

    20.

    Prevention of coronary artery reocclusion and reduction in late coronary artery stenosis after thrombolytic therapy in patients with acute myocardial infarction. A randomized study of maintenance infusion of recombinant human tissue-type plasminogen activator.

    Johns JA, Gold HK, Leinbach RC, Yasuda T, Gimple LW, Werner W, Finkelstein D, Newell J, Ziskind AA, Collen D.

    Circulation. 1988 Sep;78(3):546-56.PMID: 3136953 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity